Publications

Efficacy and Safety of Atazanavir-Based Highly Active Antiretroviral Therapy in Patients with Virologic Suppression Switched from a Stable, Boosted or Unboosted Protease Inhibitor Treatment Regimen: The Swan Study (Ai424-097) 48-Week Results

AuthID
P-004-9K0

Author(s)

Gatell, J

Salmon Ceron, D

Lazzarin, A

Van Wijngaerden, E

Antunes, F

Leen, C

Horban, A

Wirtz, V

Odeshoo, L

Van den Dungen, M

Gruber, C

Ledesma, E

Group Author(s)

SWAN Study Grp

Document Type

Article

Year published

2007

Published

in CLINICAL INFECTIOUS DISEASES, ISSN: 1058-4838

Volume: 44, Issue: 11, Pages: 1484-1492 (9)

Indexing

Wos^®

Scopus^®

Crossref^®

Pubmed^®

Google Scholar^®

Metadata
Sources

Publication Identifiers

DOI: 10.1086/517497

Pubmed: 17479947

Scopus: 2-s2.0-34249078589

Wos: WOS:000246198800015

Source Identifiers

ISSN: 1058-4838

Export Publication Metadata

Marked List

Add to Marked List

Info

At this moment we don't have any links to full text documens.

Efficacy and Safety of Atazanavir-Based Highly Active Antiretroviral Therapy in Patients with Virologic Suppression Switched from a Stable, Boosted or Unboosted Protease Inhibitor Treatment Regimen: The Swan Study (Ai424-097) 48-Week Results

Useful Links

Get Help

Federated Authentication (Click on the image)

Efficacy and Safety of Atazanavir-Based Highly Active Antiretroviral Therapy in Patients with Virologic Suppression Switched from a Stable, Boosted or Unboosted Protease Inhibitor Treatment Regimen: The Swan Study (Ai424-097) 48-Week Results

Useful Links

Get Help